Danaher Co. (NYSE:DHR) Shares Acquired by Legacy Financial Advisors Inc.

Legacy Financial Advisors Inc. lifted its position in Danaher Co. (NYSE:DHR) by 5.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,585 shares of the conglomerate’s stock after acquiring an additional 127 shares during the period. Legacy Financial Advisors Inc.’s holdings in Danaher were worth $646,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Gilbert & Cook Inc. increased its stake in shares of Danaher by 4.9% in the fourth quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after acquiring an additional 86 shares during the period. Accretive Wealth Partners LLC grew its position in Danaher by 12.9% during the 4th quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock worth $840,000 after purchasing an additional 414 shares during the period. Gryphon Financial Partners LLC raised its stake in shares of Danaher by 19.1% during the 4th quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock valued at $675,000 after buying an additional 468 shares during the last quarter. TrinityPoint Wealth LLC lifted its holdings in shares of Danaher by 12.4% in the 4th quarter. TrinityPoint Wealth LLC now owns 1,469 shares of the conglomerate’s stock valued at $340,000 after buying an additional 162 shares during the period. Finally, Aigen Investment Management LP purchased a new stake in shares of Danaher in the fourth quarter worth about $320,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 in the last three months. 11.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

DHR has been the subject of several recent research reports. TD Cowen lifted their price target on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Robert W. Baird boosted their target price on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Wells Fargo & Company began coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Stock Performance

NYSE:DHR opened at $272.63 on Friday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a market cap of $201.93 billion, a P/E ratio of 46.21, a P/E/G ratio of 4.48 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average price is $267.62 and its 200-day moving average price is $257.16.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the firm posted $2.05 EPS. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. On average, sell-side analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is currently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.